Author:
Kokkas B.,Kotridis P.,Karamouzis M.,Kanonidis I.,Sakadamis G.,Dadous G.,Haritos S.,Kyriakoui P.,Theodossiadis ,Papadopoulos P. C.,Mirtsou-Fidani V.,Papadopoulos C. L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference20 articles.
1. Papadopoulos C.L., Kokkas B, Kotridis P, et al. (1995): Plasma atrial natriuretic peptide in essential hypertension after angiotensin converting enzyme inhibition. Intern. J. Angiology, 4, 44–45
2. Papadopoulos C.L, Kokkas B, Kotridis P, et al. (1995): The effect of β1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology, 4, 165–168
3. Papadopoulos C.L, Kokkas B, Kotridis P, et al. (1998): The effect of β1-blocker/β2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther., 12, 345–346
4. Papadopoulos C.L., Kokkas B, Anogiannakis G. (2000): Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol., 13, 107–110
5. McTavish D, Sorkin E. (1989): Verapamil. An update review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs, 38, 19–76
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献